newsfilter
← Latest News
PR Newswire·

Medivir has determined the recommended phase 2 dose for fostrox in combination with Lenvima in HCC

STOCKHOLM, Feb. 20, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that the